Efficacy of eculizumab discontinuation in atypical hemolytic uremic syndrome: a systematic review and meta-analysis.

ABSTRACT:

Abstract

Atypical hemolytic uremic syndrome (aHUS), a life-threatening complement-mediated disorder, is now treatable with terminal complement inhibitors like eculizumab. Although effective, these therapies are costly, and increase susceptibility to infections, notably meningococcal disease, raising concerns about long-term use. The optimal duration of complement inhibition remains unclear, prompting efforts to explore the possibility of treatment discontinuation. We conducted a systematic review and meta-analysis to evaluate the benefits and risks of stopping terminal complement inhibitor therapy in aHUS. We searched PubMed, Scopus, and CINAHL for studies of continuing vs stopping anticomplement treatment in aHUS. Of 3303 identified studies, 13 observational studies (3 case contro

SUBMITTER: Hockman A 

PROVIDER: S-EPMC12719173 | biostudies-literature | 2025 Dec

REPOSITORIES: biostudies-literature